Save Up To 70% with generic medications and up to 40% with brand name drugs. Get FREE WorldWide shipping on $149 or more...
Blood / Hematology » Ablynx Announces Positive Phase I...
Home » News » Ablynx Announces Positive Phase I Results...
Ablynx Announces Positive Phase I Results For Subcutaneous Administration Of Its Anti-Thrombotic Nanobody(R) (Alx-0681)
Ablynx [Euronext Brussels: ABLX] announced the positive results from its double- blind, randomized, placebo-controlled, single and multiple dose Phase I study with ALX-0681, a subcutaneous formulation of its novel anti-thrombotic Nanobody® that selectively targets von Willebrand factor (vWF).
Read full article @ MedicalNewsToday
Read Also Other "Blood / Hematology" News
-
ARYx Therapeutics Announces Results Of Phase 2/3 Clinical Trial On Anticoagulant Agent Tecarfarin
ARYx Therapeutics, Inc. (NASDAQ:ARYX), a biopharmaceutical company,...
